CHMP recommends Cyramza (ramucirumab) and erlotinib combination therapy first-line treatment of NSCLC adult patients

recently, Eli Lilly announced that the EuropeanMedicines(http://Administration (EMAhttp://
http://
) recommended single anti-
drug(http://) and tyrosine coenzyme inhibitors (TKIs) erlotinib in a combination of therapy for eGFR-carrying patientsAbout CyramzaVascular Endothelial Growth Factor (VEGF) receptor 2 antagonist Cyramza, an antiangiogenic therapyCyramza blocks the activation of this signaling pathway by blocking the specific binding of VEGF receptor s2 and VEGF-A, VEGF-C and VEGF-DBlocking the connection of veGF proteins to blood vessels helps to inhibit tumor growth by slowing bloodsupply of(http:// Cyramza has been approved by the U.S FDA (http:// as a second-line therapy for gastric, NSCLC, colorectal cancer, and hepatocellular carcinoma (HCC) 　　CHMP's advice was based on a positive finding from a randomized, double-blind, three-stage clinical trial (http:// involving 449 patients with eGFR gene mutations (exogenous 19 missing or exogenous 21 L858R replacement mutations) results showed that the combination therapy of Cyramza and erlotinib resulted in a significant improvement (19.4 months) in the patient's progression-free survival (19.4 months) compared to the active control group consisting of placebo and erlotinib (12.4 months) improved in the combination therapy group in terms of remission duration, second progression or time of death (PFS2), and secondary or exploratory endpoints such as time for targeted treatment (time on targeted therapy)